• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Feb. 4, 2014

View Archived Issues

Ablynx and Merck cozy up in second deal; up to $2.3B for Nanobodies

LONDON – Ablynx NV has formed a second partnership with Merck & Co. Inc, which will see the two collaborate to develop cancer immunotherapies in a deal with a headline value of $2.3 billion, almost quadruple that of their first agreement in neuroscience. Read More

Pharma relying on external innovation, report shows

LONDON – Pharma’s dependence on biotechs and academics for innovation is highlighted in an analysis of the 94 novel drugs approved in Europe from 2010 to 2012, which shows that while 87 percent of the approvals were granted to pharmaceutical companies, more than half of the products had their origins outside corporate laboratories. Read More

FDA wants broader study populations, with more elderly

The FDA’s Center for Drug Evaluation and Research (CDER) is ramping up efforts to make certain that clinical trials include wide enough breadths of patient populations, and don’t unnecessarily keep out subjects with multiple chronic conditions (MCCs) who could turn up important data that would otherwise be missed. Read More

CRS: Biosimilar competition not likely in the short-term

With an eye on enhancing biologic competition, the FTC is diving into some of the issues that will shape the biosimilar market in the U.S. But the Congressional Research Service (CRS) isn’t holding its breath as it waits for the competition to hit. Read More

Cell cycle has need for speed in iPS cell reprogramming

Last week, the news that exposing mature cells to stressful environments such as low pH can induce a stem cell-like state was greeted with much excitement, as stimulus-triggered acquisition of pluripotency cells (STAP cells) joined embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells) as a cell type that might ultimately provide materials for autologous cell transplants. Read More

Other news to note

Endo Health Solutions, of Malvern, Pa., said its Qualitest subsidiary completed the acquisition of Boca Pharmacal, of Coral Springs, Fla., a specialty pharmaceutical company, for approximately $225 million in cash. Read More

Stock Movers

Read More

Clinic roundup

Cel-Sci Corp., of Vienna, Va., said the institutional review board of the U.S. Navy’s Naval Medical Center, of San Diego, approved the start of a Phase I dose-escalation study of immunotherapy Multikine (leukocyte interleukin, injection) in HIV/human papillomavirus co-infected men and women with perianal warts. Read More

Financings roundup

Alimera Sciences Inc., of Atlanta, said it closed a private placement of common stock on Jan. 31, with gross proceeds from the offering totaling about $37.5 million. Read More

Pharma: Other news to note

Forest Laboratories Inc., of New York, said it, along with Merz Pharma GmbH & Co. KgaA, of Frankfurt, Germany, and Adamas Pharmaceuticals Inc., of Emeryville, Calif., jointly filed a lawsuit in the U.S. District Court for the District of Delaware against several companies for the infringement of some or all of the patents relating to Forest’s Namenda XR (memantine HCl extended-release capsule) product. Read More

Pharma: Clinic roundup

Pfizer Inc., of New York, said the randomized Phase II (PALOMA-1) of palbociclib achieved its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in progression-free survival for the combination of palbociclib and letrozole compared to letrozole alone in postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or newly diagnosed metastatic breast cancer. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • Pill with British pound sign

    Pharma execs speak out: UK pricing rebates scare investors

    BioWorld
    The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • DNA mutations or genetic disorder concept art

    Regenxbio’s Duchenne gene therapy data positive as shares falter

    BioWorld
    Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe